

SIGRID KIERMAYR, PhD

EXPERIENCE

Head of Department Communicable Diseases & Disease Control
Federal Ministry of Social Affairs, Health, Care and Consumer Protection
since September 2021

Covid-19 Crisis Team
Federal Ministry of Social Affairs, Health, Care and Consumer Protection
since April 2021

Head of Analytics & Development, Valneva Austria GmbH
10/2019 - 02/2021

Head of Quality Control, Valneva Austria GmbH
06/2016 - 09/2019

Head of Clinical Serology, Valneva Austria GmbH (former Intercell AG)
01/2014 - 05/2016

(Senior) Staff Scientist Clinical Serology, Valneva Austria GmbH (former Intercell AG)
02/2007 - 12/2013 (Maternity Leave 6/2009-10/2010)

Scientific Staff, Institute of Virology, Medical University of Vienna
03/2005 - 09/2005 (Maternity Leave 9/2005-2/2007)

EDUCATION

Institute of Virology, Medical University of Vienna: *PhD Studies* „Mutationsanalyse des FSME-Virus
Oberflächenglykoproteins prM“
4/2002 - 3/2005

Institute of Virology, University of Vienna: *Master Thesis* „Struktur-Funktionsanalyse des FSME-Virus
Oberflächenglykoproteins prM“
11/2000 - 3/2002

University of Vienna, *Studies of Biochemistry*
1995 – 2002

Université des Sciences et Technologies de Lille, France (Erasmus)
SS 1998

LIST OF PUBLICATIONS AND AWARDS

Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.

Taucher C, Barnett ED, Cramer JP, Eder-Lingelbach S, Jelinek T, Kadlec V, Kiermayr S, Mills DJ, Pandis D, Reiner D, Dubischar KL. Travel Med Infect Dis. 2020 Mar-Apr;34:101616.

Safety and immunogenicity of an inactivated Vero cell derived Japanese encephalitis vaccine (IXIARO® JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.

Jelinek T, Cromer MA, Cramer JP, Mills DJ, Lessans K, Gherardin AW, Barnett ED, Hagmann SHF, Askling HH, Kiermayr S, Kadlec V, Eder-Lingelbach S, Taucher C, Dubischar KL. Travel Med Infect Dis. 2018 Mar-Apr;22:18-24.

Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.

Kadlec V, Borja-Tabora CF, Eder-Lingelbach S, Gatchalian S, Kiermayr S, Sablan B Jr, Kundi M, Taucher C, Dubischar KL. Pediatr Infect Dis J. 2018 Sep;37(9):e233-e240.

Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.

Dubischar KL, Kadlec V, Sablan JB, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Kiermayr S, Spruth M, Westritschnig K. Pediatr Infect Dis J. 2017 Sep;36(9):898-904.

Changing the protease specificity for activation of a flavivirus, tick-borne encephalitis virus.

Fischl W, Elshuber S, Schrauf S, Mandl CW. J Virol. 2008 Sep;82(17):8272-82.

Resuscitating mutations in a furin cleavage-deficient mutant of the flavivirus tick-borne encephalitis virus.

Elshuber S, Mandl CW. J Virol. 2005 Sep;79(18):11813-23.

Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus.

Elshuber S, Allison SL, Heinz FX, Mandl CW. J Gen Virol. 2003 Jan;84(Pt 1):183-191.

Förderungspreis 2002 der Gesellschaft Österreichischer Chemiker (GöCh) für die Diplomarbeit "Struktur-Funktionsanalyse des FSME-Virus-Oberflächenglykoproteins prM"

Österreichischer Mikrobiologie-Preis 2006 der Österreichischen Gesellschaft für Hygiene, Mikrobiologie und Präventivmedizin für die Publikation "Resuscitating Mutations in a Furin Cleavage-Deficient Mutant of the Flavivirus Tick-Borne Encephalitis Virus"